Vol 10, No 6 (December 31, 2021): Chinese Clinical Oncology

Editorial on Inflammatory Breast Cancer1

“Why and What” for the optimal management of inflammatory breast cancer
Naoto T. Ueno, Angela Alexander
Chinese Clinical Oncology  
2021;
10
(6)
:54
.

Review Article on Inflammatory Breast Cancer1

What is the best systemic treatment for newly diagnosed inflammatory breast cancer?—a narrative review
Sudpreeda Chainitikun, Siyamol Mingmalairak, Napa Parinyanitikul
Chinese Clinical Oncology  
2021;
10
(6)
:55
.
Baseline FDG PET-CT imaging is necessary for newly diagnosed inflammatory breast cancer patients: a narrative review
Miral M. Patel, Huong T. Le-Petross
Chinese Clinical Oncology  
2021;
10
(6)
:56
.
Contemporary surgical management of inflammatory breast cancer: a narrative review
Taiwo Adesoye, Shelby Irwin, Susie X. Sun, Anthony Lucci, Mediget Teshome
Chinese Clinical Oncology  
2021;
10
(6)
:57
.
Why diagnosing inflammatory breast cancer is hard and how to overcome the challenges: a narrative review
Huong T. Le-Petross, Wintana Balema, Wendy A. Woodward
Chinese Clinical Oncology  
2021;
10
(6)
:58
.
What is the best treatment recommendation for HER2+ IBC with residual disease?—a narrative review
Danielle B. Zakon, Vicente Valero
Chinese Clinical Oncology  
2021;
10
(6)
:59
.
How should radiation be done for inflammatory breast cancer patients?—a narrative review of modern literature
Kelsey L. Corrigan, Wendy A. Woodward, Michael C. Stauder
Chinese Clinical Oncology  
2021;
10
(6)
:60
.

Disclosure:

1. The series “Inflammatory Breast Cancer” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Professor Naoto T. Ueno served as the unpaid Guest Editor for the series.